Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
One Percent Rule Checklist For Safer Forex Trading Risk 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
NEW YORK, April 19, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of TherapeuticsMD, Inc. (“TherapeuticsMD”) (NYSEMKT:TXMD) between July 7, 2016 and April 9, 2017. You are hereby notified that Levi & Korsinsky has commenced the action Paoli v. TherapeuticsMD, Inc., et al. (Case No. 9:17-cv-80473-RLR) in the USDC for the Southern District of Florida. To get more information go to:
http://www.zlk.com/pslra-sa/therapeuticsmd-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the class period, TherapeuticsMD engaged in a scheme to deceive the market and cause the Company’s stock to trade at artificially inflated prices. In particular, the complaint alleges that TherapeuticsMD made false and/or misleading statements and/or failed to disclose that: (i) the Company’s New Drug Application (NDA) submission for TX-004HR was deficient; (ii) the NDA submission for TX-004HR was not supported by the complete TX-004HR clinical program and/or the clinical program was deficient; (iii) the deficient NDA would likely cause a delay of the FDA’s potential approval of the TX-0004HR NDA.
On April 10, 2017, TherapeuticsMD issued a press release announcing that the U.S. Food and Drug Administration had identified deficiencies in its NDA for TX-004HR. Following this news, shares of TherapeuticsMD fell more than 19% to close at $6.20 per share on April 10, 2017.
Take Action: if you suffered a loss in TherapeuticsMD you have until June 19, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
